AMPH Stock Overview

Amphastar Pharmaceuticals' stock has declined over 25% since early November, despite solid earnings and sales growth, presenting a potential buying opportunity. Q3 results were impacted somewhat by the effects of Hurricane Helene, after easily exceeding top and bottom-line expectations in Q2. The stock is cheap on a P/E basis, but there are some caveats, including patent expiration in early 2026 on a key product.

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4th, 2024 at 11:30 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.

Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.96 per share, missing the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $1.15 per share a year ago.

Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Amphastar Pharmaceuticals shows promising growth potential with its diverse product offerings, including the nasally administered glucagon treatment BAQSIMI and the over-the-counter inhalant Primatene MIST. The company's solid balance sheet, with a current ratio of 3.52 and manageable debt levels, provides flexibility to navigate market changes. Risks include reliance on single-source supplies, dependency on Lilly for BAQSIMI manufacturing, and the impact of reference brand demand on generic products.

RANCHO CUCAMONGA, CA / ACCESSWIRE / August 28, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024 at 10:15 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.

The three-week market selloff sparked by recession fears was led by plunging tech, cyclical, industrial, and energy stocks. High-quality stocks clobbered in the past 30 days, and others beaten down in the past year offer potential buying opportunities. We identified 6 stocks down by double digits within the last year with Buy or Strong Buy Quant Ratings, high forward growth metrics, and attractive valuations.